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OBSERVATIONS
“Mind the Gap”
When Managing
Ketoacidosis in Type
1 Diabetes
S
ubstance abuse has increased
among type 1 diabetic patients (1)
and can lead to life-threatening dia-
betic ketoacidosis (DKA). This is the ﬁrst
study examining the impact of substance
abuse on acidosis in DKA.
Aretrospectivereviewwasperformed
on 19 type 1 diabetic patients who pre-
sented with DKA (glucose 15 mmol/l,
presence of urinary and/or plasma ke-
tones , and pH 7.2) during a 10-month
period. Of these, patients reported non-
adherence to 1 dose of insulin before
presentation. Ten patients reported illicit
drug use in the 48 h before presentation,
including cannabis (n  8), ecstasy (n 
6), ketamine (n  6), benzodiazepines
(n  3) , and heroin (n  3); seven pa-
tients were poly-drug users.
Druguserswereyoungerthannonus-
ers (21  6 vs. 32  10 years, respec-
tively, P  0.01) and tended to have
higher plasma glucose concentrations
(32.4  7.7 vs. 26.1  10.1 mmol/l, re-
spectively, P  0.1). A1C was not differ-
ent (12.9  2.8 vs. 11.7  1.0%,
respectively, P  0.3). Despite signiﬁ-
cantly lower plasma -hydroxybutyrate
concentrations (3.4  1.0 vs. 4.9  1.2
mmol/l, respectively, P  0.01), drug us-
ers had lower arterial pH values (7.02 
0.14 vs. 7.19  0.05, respectively, P 
0.002) and lower bicarbonate concentra-
tions (3.9  2.2 vs. 8.6  2, respectively,
P  0.0007). Lactatemia was absent in
both groups. Calculated acidosis-ketosis
gap (AKG) (arterial pH  plasma -hy-
droxybutyrate concentration) was signif-
icantlyhigherindrugusers(3.61.0vs.
2.5  1.2, P  0.04). Eighty percent of
drug users had an AKG3, in contrast to
33% of nondrug users (P  0.0009).
Designer drugs can cause serious
complications in type 1 diabetes, espe-
cially in “rave” parties (1). Underreport-
ing is common due to fear of retribution
(2). Concurrent benzodiazepine use can
mask sympathetic overactivity classically
reported with stimulant use, making di-
agnosis difﬁcult.
Our study documented a greater gap
between arterial pH and plasma -hy-
droxybutyrate concentration in drug us-
ers. Although drug users presented with
more severe acidosis, it was only accom-
panied by relatively mild ketosis.
The mechanism by which designer
drugs cause acidosis is poorly under-
stood. DKA may be precipitated by the
combination of insulin noncompliance
during rave parties; hyperglycemic prop-
erties of drugs such as cannabis, heroin,
and ecstasy (3,4); and ketosis caused by
stimulant-enhanced lipolysis from sym-
pathetic overactivity. Ketamine can cause
severeacidosis,whichcouldbesecondary
to renal bicarbonate and -hydroxybu-
tyrate wasting (5).
Although only limited conclusions
can be drawn from our study due to the
small number of patients, any observa-
tions that guide assessment will aid clini-
cal practice given the limitations of
research in substance abuse. Despite
treatment of DKA becoming more suc-
cessful, standardized insulin infusion
protocolsdonottriggersuspicionofother
etiology. A modern approach to DKA
should emphasize not only prompt treat-
ment with insulin, but also identiﬁcation
of precipitants beyond noncompliance
and infection. Calculation of the AKG
mayhelpidentifynonreportersorvictims
of drink spiking, whose acidosis could be
partly due to drug use. Although treat-
ment of most drug toxicity is supportive,
failure to recognize drug use can lead to
rapid clinical deterioration. Early identi-
ﬁcation of such patients also facilitates re-
ferral to detoxiﬁcation and counseling
services.
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